

SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by
UK REACH Regulations SI 2019/758



Ribavirin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.4	14.04.2025	9372509-00010	Date of first issue: 27.08.2021

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Ribavirin Solid Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-
stance/Mixture : Pharmaceutical

Recommended restrictions
on use : Not applicable

1.3 Details of the supplier of the safety data sheet

Company : MSD
120 Moorgate
EC2M 6UR London, United Kingdom

Telephone : +44 (0) 2081548000

E-mail address of person
responsible for the SDS : EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

+1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008) as amended by GB-CLP Regulation, UK SI 2019/720, and UK SI 2020/1567)

Germ cell mutagenicity, Category 2 H341: Suspected of causing genetic defects.

Reproductive toxicity, Category 1B H360Df: May damage the unborn child. Suspected of damaging fertility.

Specific target organ toxicity - single exposure, Category 3 H335: May cause respiratory irritation.

Specific target organ toxicity - repeated exposure, Category 1 H372: Causes damage to organs through prolonged or repeated exposure.

SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by
UK REACH Regulations SI 2019/758



Ribavirin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.4	14.04.2025	9372509-00010	Date of first issue: 27.08.2021

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008) as amended by GB-CLP Regulation, UK SI 2019/720, and UK SI 2020/1567)

Hazard pictograms :

Signal word : Danger

Hazard statements :
H335 May cause respiratory irritation.
H341 Suspected of causing genetic defects.
H360Df May damage the unborn child. Suspected of damaging fertility.
H372 Causes damage to organs through prolonged or repeated exposure.

Precautionary statements : **Prevention:**
P201 Obtain special instructions before use.
P260 Do not breathe dust.
P264 Wash skin thoroughly after handling.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:
P304 + P340 + P312 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER/ doctor if you feel unwell.
P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Hazardous components which must be listed on the label:
Ribavirin

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No. EC-No.	Classification	Concentration (% w/w)
---------------	-------------------	----------------	--------------------------

SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by
UK REACH Regulations SI 2019/758



Ribavirin Solid Formulation

Version 4.4 Revision Date: 14.04.2025 SDS Number: 9372509-00010 Date of last issue: 28.09.2024
Date of first issue: 27.08.2021

	Index-No. Registration number		
Ribavirin	36791-04-5	Acute Tox. 4; H302 Muta. 2; H341 Repr. 1B; H360Df STOT SE 3; H335 STOT RE 1; H372 (Blood)	>= 50 - < 70
Substances with a workplace exposure limit :			
Cellulose	9004-34-6 232-674-9		>= 10 - < 20

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- If inhaled : If inhaled, remove to fresh air.
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.
- In case of eye contact : If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

- Risks : Contact with dust can cause mechanical irritation or drying of the skin.
Dust contact with the eyes can lead to mechanical irritation.
- May cause respiratory irritation.
Suspected of causing genetic defects.

SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by
UK REACH Regulations SI 2019/758



Ribavirin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.4	14.04.2025	9372509-00010	Date of first issue: 27.08.2021

May damage the unborn child. Suspected of damaging fertility.
Causes damage to organs through prolonged or repeated exposure.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

Unsuitable extinguishing media : None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides
Metal oxides

5.3 Advice for firefighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.

SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by
UK REACH Regulations SI 2019/758



Ribavirin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.4	14.04.2025	9372509-00010	Date of first issue: 27.08.2021

Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
If spillage enters rivers or watercourses, inform the Environment Agency (emergency telephone number 0800 807060).

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Surround spill with absorbents and place a damp covering over the area to minimise entry of the material into the air. Add excess liquid to allow the material to enter into solution. Soak up with inert absorbent material. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures	: Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
Local/Total ventilation	: If sufficient ventilation is unavailable, use with local exhaust ventilation.
Advice on safe handling	: Do not get on skin or clothing. Do not breathe dust. Do not swallow. Avoid contact with eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment Keep container tightly closed. Already sensitised individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respiratory irritants or sensitisers. Minimize dust generation and accumulation. Keep container closed when not in use.

SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by
UK REACH Regulations SI 2019/758



Ribavirin Solid Formulation

Version 4.4 Revision Date: 14.04.2025 SDS Number: 9372509-00010 Date of last issue: 28.09.2024
Date of first issue: 27.08.2021

Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers : Keep in properly labelled containers. Store locked up. Keep tightly closed. Keep in a cool, well-ventilated place. Store in accordance with the particular national regulations.

Advice on common storage : Do not store with the following product types:
Strong oxidizing agents
Self-reactive substances and mixtures
Organic peroxides
Explosives
Gases

7.3 Specific end use(s)

Specific use(s) : No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

dust of any kind 10 mg/m³
Value type (Form of exposure): TWA (Inhalable)
Basis: GB EH40

4 mg/m³
Value type (Form of exposure): TWA (Respirable fraction)
Basis: GB EH40

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Ribavirin	36791-04-5	Wipe limit	400 µg/100 cm ²	Internal
		TWA	40 µg/m ³ (OEB 3)	Internal
Cellulose	9004-34-6	TWA (inhalable dust)	10 mg/m ³	GB EH40
		TWA (Respirable dust)	4 mg/m ³	GB EH40

SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by
UK REACH Regulations SI 2019/758



Ribavirin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.4	14.04.2025	9372509-00010	Date of first issue: 27.08.2021

		STEL (inhalable dust)	20 mg/m3	GB EH40
--	--	-----------------------	----------	---------

8.2 Exposure controls

Engineering measures

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

Personal protective equipment

Eye/face protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Hand protection	:	
Material	:	Chemical-resistant gloves
Remarks	:	Consider double gloving.
Skin and body protection	:	Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Respiratory protection	:	If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection. Equipment should conform to BS EN 143
Filter type	:	Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Appearance	:	powder
Colour	:	white
Odour	:	No data available
Odour Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available

SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by
UK REACH Regulations SI 2019/758



Ribavirin Solid Formulation

Version 4.4	Revision Date: 14.04.2025	SDS Number: 9372509-00010	Date of last issue: 28.09.2024 Date of first issue: 27.08.2021
----------------	------------------------------	------------------------------	---

Evaporation rate	:	Not applicable
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	Not applicable
Relative vapour density	:	Not applicable
Relative density	:	No data available
Density	:	No data available
Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	Not applicable
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.

9.2 Other information

Particle size	:	No data available
---------------	---	-------------------

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions	:	May form explosive dust-air mixture during processing, handling or other means.
---------------------	---	---

SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by
UK REACH Regulations SI 2019/758



Ribavirin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.4	14.04.2025	9372509-00010	Date of first issue: 27.08.2021

dling or other means.
Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : Heat, flames and sparks.
Avoid dust formation.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on toxicological effects

Information on likely routes of exposure : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg
Method: Calculation method

Components:

Ribavirin:

Acute oral toxicity : LD50 (Rat): 4,116 - 5,584 mg/kg

LD50 (Mouse): > 10,000 mg/kg

LD50 (Dog): >= 1,500 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Acute toxicity (other routes of administration) : LD50 (Rat): 1,554 - 1,758 mg/kg
Application Route: Intraperitoneal

LD50 (Mouse): 1,268 mg/kg
Application Route: Intraperitoneal

Cellulose:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by
UK REACH Regulations SI 2019/758



Ribavirin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.4	14.04.2025	9372509-00010	Date of first issue: 27.08.2021

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Skin corrosion/irritation

Not classified based on available information.

Components:

Ribavirin:

Remarks : No data available
May irritate skin.

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Ribavirin:

Remarks : No data available
May irritate eyes.

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

Ribavirin:

Remarks : No data available

Germ cell mutagenicity

Suspected of causing genetic defects.

Components:

Ribavirin:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Test system: Rodent cell line
Result: positive

Test Type: Chromosomal aberration
Test system: Human lymphocytes

SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by
UK REACH Regulations SI 2019/758



Ribavirin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.4	14.04.2025	9372509-00010	Date of first issue: 27.08.2021

Result: negative

Genotoxicity in vivo : Test Type: dominant lethal test
Species: Rat
Result: negative

Test Type: Mouse Lymphoma
Species: Mouse
Result: positive

Test Type: Micronucleus test
Species: Mouse
Result: positive

Germ cell mutagenicity- Assessment : Positive result(s) from in vivo mammalian somatic cell mutagenicity tests.

Cellulose:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Ingestion
Result: negative

Carcinogenicity

Not classified based on available information.

Components:

Ribavirin:

Species : Mouse
Application Route : Oral
Exposure time : 6 Months
LOAEL : 75 mg/kg body weight
Result : negative
Target Organs : Blood, Testes
Remarks : The mechanism or mode of action may not be relevant in humans.

Species : Rat
Application Route : Oral
Exposure time : 2 Years
NOAEL : 10 mg/kg body weight
Result : negative
Remarks : The mechanism or mode of action may not be relevant in humans.

SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by
UK REACH Regulations SI 2019/758



Ribavirin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.4	14.04.2025	9372509-00010	Date of first issue: 27.08.2021

Species : Mouse
Application Route : Oral
Exposure time : 18 Months
Result : negative
Remarks : The mechanism or mode of action may not be relevant in humans.

Cellulose:

Species : Rat
Application Route : Ingestion
Exposure time : 72 weeks
Result : negative

Reproductive toxicity

May damage the unborn child. Suspected of damaging fertility.

Components:

Ribavirin:

Effects on fertility : Test Type: Fertility
Species: Rat, male
Application Route: Intraperitoneal injection
Fertility: LOAEL: < 20 mg/kg body weight
Symptoms: Reduced fertility
Result: positive

Test Type: Fertility
Species: Mouse, male
Application Route: Oral
Fertility: LOAEL: 35 mg/kg body weight
Symptoms: Reduced fertility
Result: positive

Test Type: Fertility
Species: Rat, females
Application Route: Oral
Fertility: NOAEL: 10 mg/kg body weight
Result: Animal testing did not show any effects on fertility.

Test Type: Fertility
Species: Rat, male
Application Route: Oral
Fertility: NOAEL: 160 mg/kg body weight
Result: Animal testing did not show any effects on fertility.

Effects on foetal development : Test Type: Development
Species: Rat, female
Application Route: Oral
Developmental Toxicity: LOAEL: <= 1 mg/kg body weight
Symptoms: Reduced body weight, Reduced number of viable fetuses, Skeletal malformations

SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by
UK REACH Regulations SI 2019/758



Ribavirin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.4	14.04.2025	9372509-00010	Date of first issue: 27.08.2021

Result: Embryotoxic effects and adverse effects on the off-spring were detected.

Test Type: Development
Species: Rabbit, female
Application Route: Oral
General Toxicity Maternal: LOAEL: 1 mg/kg body weight
Developmental Toxicity: LOAEL: 1 mg/kg body weight
Symptoms: Reduced body weight, Skeletal malformations
Result: Embryotoxic effects and adverse effects on the off-spring were detected.

Test Type: Development
Species: Hamster
Application Route: Oral
Developmental Toxicity: LOAEL: 2.5 mg/kg body weight
Symptoms: Skeletal and visceral variations, Total Resorptions / resorption rate
Result: Embryotoxic effects and adverse effects on the off-spring were detected.

Test Type: Embryo-foetal development
Species: Rat
Application Route: Oral
General Toxicity Maternal: NOAEL: 0.3 mg/kg body weight
Embryo-foetal toxicity: LOAEL: 1 mg/kg body weight
Symptoms: Skeletal malformations
Result: positive

Reproductive toxicity - Assessment : Some evidence of adverse effects on sexual function and fertility, based on animal experiments., Clear evidence of adverse effects on development, based on animal experiments.

Cellulose:

Effects on fertility : Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

Effects on foetal development : Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Ingestion
Result: negative

STOT - single exposure

May cause respiratory irritation.

Components:

Ribavirin:

Assessment : May cause respiratory irritation.

SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by
UK REACH Regulations SI 2019/758



Ribavirin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.4	14.04.2025	9372509-00010	Date of first issue: 27.08.2021

STOT - repeated exposure

Causes damage to organs through prolonged or repeated exposure.

Components:

Ribavirin:

Exposure routes	: Ingestion
Target Organs	: Blood
Assessment	: Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Ribavirin:

Species	: Monkey
LOAEL	: 30 mg/kg
Exposure time	: 10 d
Target Organs	: Blood, Gastrointestinal tract

Species	: Rat
NOAEL	: 7.6 mg/kg
Application Route	: Inhalation
Exposure time	: 90 d
Target Organs	: Blood, Lungs

Species	: Dog
NOAEL	: 5 mg/kg
Application Route	: Oral
Exposure time	: 1 yr
Target Organs	: Blood, Gastrointestinal tract

Species	: Mouse
NOAEL	: 20 mg/kg
Application Route	: Oral
Exposure time	: 18 Months
Target Organs	: Blood, Cardio-vascular system

Cellulose:

Species	: Rat
NOAEL	: >= 9,000 mg/kg
Application Route	: Ingestion
Exposure time	: 90 Days

Aspiration toxicity

Not classified based on available information.

SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by
UK REACH Regulations SI 2019/758



Ribavirin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.4	14.04.2025	9372509-00010	Date of first issue: 27.08.2021

Experience with human exposure

Components:

Ribavirin:

Inhalation	:	Symptoms: Headache, Dizziness Remarks: Based on Human Evidence
Skin contact	:	Remarks: May cause eye irritation. Based on Human Evidence
Eye contact	:	Remarks: May cause eye irritation. Based on Human Evidence
Ingestion	:	Symptoms: blood effects, immune system effects, anorexia, Dizziness, insomnia, Fatigue, Headache, Itching, Rash, liver function change, Gastrointestinal disturbance

SECTION 12: Ecological information

12.1 Toxicity

Components:

Ribavirin:

Toxicity to fish	:	LC50 (Oncorhynchus mykiss (rainbow trout)): > 119 mg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): > 117 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
Toxicity to algae/aquatic plants	:	EC50 (Pseudokirchneriella subcapitata (green algae)): > 119 mg/l Exposure time: 96 h Method: OECD Test Guideline 201 NOEC (Pseudokirchneriella subcapitata (green algae)): 6.9 mg/l Exposure time: 96 h Method: OECD Test Guideline 201
Toxicity to microorganisms	:	EC50 : > 1,000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209

Cellulose:

Toxicity to fish	:	LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l Exposure time: 48 h Remarks: Based on data from similar materials
------------------	---	--

SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by
UK REACH Regulations SI 2019/758



Ribavirin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.4	14.04.2025	9372509-00010	Date of first issue: 27.08.2021

12.2 Persistence and degradability

Components:

Cellulose:

Biodegradability : Result: Readily biodegradable.

12.3 Bioaccumulative potential

Components:

Ribavirin:

Partition coefficient: n-octanol/water : log Pow: 0.971

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment

Product:

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Other adverse effects

Product:

Endocrine disrupting potential : This substance/mixture does not contain components considered to have endocrine disrupting properties for environment according to UK REACH Article 57(f).

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product	: Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.
Contaminated packaging	: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number

ADN : Not regulated as a dangerous good

SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by
UK REACH Regulations SI 2019/758



Ribavirin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.4	14.04.2025	9372509-00010	Date of first issue: 27.08.2021

ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
IATA	:	Not regulated as a dangerous good

14.2 UN proper shipping name

ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
IATA	:	Not regulated as a dangerous good

14.3 Transport hazard class(es)

ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
IATA	:	Not regulated as a dangerous good

14.4 Packing group

ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
IATA (Cargo)	:	Not regulated as a dangerous good
IATA (Passenger)	:	Not regulated as a dangerous good

14.5 Environmental hazards

Not regulated as a dangerous good

14.6 Special precautions for user

Not applicable

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

Relevant EU provisions transposed through retained EU law

UK REACH List of restrictions (Annex 17)	:	Not applicable
--	---	----------------

SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by
UK REACH Regulations SI 2019/758



Ribavirin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.4	14.04.2025	9372509-00010	Date of first issue: 27.08.2021

UK REACH Candidate list of substances of very high concern (SVHC) for Authorisation	: Not applicable
The Persistent Organic Pollutants Regulations (retained Regulation (EU) 2019/1021 as amended for Great Britain)	: Not applicable
Regulation (EU) No 2024/590 on substances that deplete the ozone layer	: Not applicable
UK REACH List of substances subject to authorisation (Annex XIV)	: Not applicable
GB Export and import of hazardous chemicals - Prior Informed Consent (PIC) Regulation	: Not applicable
Control of Major Accident Hazards Regulations 2015 (COMAH)	: Not applicable

Other regulations:

Take note of The Management of Health and Safety at Work Regulations 1999 (requirements relating to new and expectant mothers at work contained in Regulation 16 to 18) and of the Pregnant Workers Directive 92/85/EEC.

Take note of The Management of Health and Safety at Work Regulations 1999 (requirements relating to protection of young people at work contained in Regulation 19) and of Directive 94/33/EC on the protection of young people at work.

The components of this product are reported in the following inventories:

AICS	: not determined
DSL	: not determined
IECSC	: not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information	: Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.
-------------------	--

Full text of H-Statements

H302	: Harmful if swallowed.
H335	: May cause respiratory irritation.
H341	: Suspected of causing genetic defects.
H360Df	: May damage the unborn child. Suspected of damaging fertility.
H372	: Causes damage to organs through prolonged or repeated exposure if swallowed.

Full text of other abbreviations

Acute Tox.	: Acute toxicity
Muta.	: Germ cell mutagenicity

SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by
UK REACH Regulations SI 2019/758



Ribavirin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.4	14.04.2025	9372509-00010	Date of first issue: 27.08.2021

Repr.	: Reproductive toxicity
STOT RE	: Specific target organ toxicity - repeated exposure
STOT SE	: Specific target organ toxicity - single exposure
GB EH40	: UK. EH40 WEL - Workplace Exposure Limits
GB EH40 / TWA	: Long-term exposure limit (8-hour TWA reference period)
GB EH40 / STEL	: Short-term exposure limit (15-minute reference period)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Classification of the mixture:

Muta. 2	H341
Repr. 1B	H360Df
STOT SE 3	H335
STOT RE 1	H372

Classification procedure:

Calculation method
Calculation method
Calculation method
Calculation method

SAFETY DATA SHEET

According to REACH Regulation (EC) No 1907/2006, as amended by
UK REACH Regulations SI 2019/758



Ribavirin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.4	14.04.2025	9372509-00010	Date of first issue: 27.08.2021

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

GB / EN